Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

7.615
-0.470-5.81%
Volume:1.31M
Turnover:10.12M
Market Cap:7.36B
PE:-63.46
High:8.055
Open:8.055
Low:7.520
Close:8.085
52wk High:15.750
52wk Low:6.230
Shares:967.00M
HK Float Shares:967.00M
Volume Ratio:3.13
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.120
ROE:-9.98%
ROA:-5.47%
PB:3.76
PE(LYR):-63.46
PS:12.14

Loading ...

Alphamab Oncology trims outstanding share count by 110,000 through HKD 0.98 million buy-back in August 2026

Bulletin Express
·
Sep 04

Alphamab Oncology Buys Back 115,000 Shares, Lifting Treasury Stock to 6.22 Million

Bulletin Express
·
Sep 02

Alphamab Oncology Files HKEX Next-Day Disclosure Return for Share Buyback at HKD 8.57

Reuters
·
Sep 02

Alphamab Oncology Buys Back 115,000 Shares for HKD 0.98 Million, Lifts Treasury Stock to 6.10 Million

Bulletin Express
·
Sep 01

Alphamab Oncology Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 8.9 Each

Reuters
·
Aug 31

Alphamab Oncology Launches HK$80.00 Million On-Market Share Repurchase Plan

Bulletin Express
·
Aug 28

Alphamab Oncology - Board Resolves to Repurchase Shares up to HK$80 Mln in Value

THOMSON REUTERS
·
Aug 28

Alphamab Oncology Launches On-Market Share Buyback of up to HK$ 80 Million

Reuters
·
Aug 28

Alphamab Oncology (SEHK:9966) Stock Rally Meets Revenue Dip And Losses

Simply Wall St.
·
Aug 28

Why Alphamab Oncology (SEHK:9966) Is Up 9.2% After Priority Review For Anbenitamab In HER2 Breast Cancer

Simply Wall St.
·
Aug 28

Alphamab Oncology Reports RMB40.46 Million 1H26 Loss Amid 15% Revenue Drop; Cash at RMB1.43 Billion Supports Expanding Oncology Pipeline

Bulletin Express
·
Aug 27

Alphamab Oncology Swings to FY26 H1 Loss of RMB 40.46 Million; Revenue Falls 15.09% to RMB 271.24 Million

Reuters
·
Aug 27

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Aug 26

Alphamab's KN026 Combination Therapy for First-Line HER2-Positive Advanced Breast Cancer Receives NMPA Filing Acceptance

Stock News
·
Aug 18

Alphamab Oncology Says China NMPA Accepts Anbenitamab NDA for First-Line HER2+ Advanced Breast Cancer

Reuters
·
Aug 18

Alphamab Oncology - Nmpa Accepts Nda for Anbenitamab (Kn026) with Hb1801 for Her2+ Advanced Breast Cancer

THOMSON REUTERS
·
Aug 18

Alphamab Oncology Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 12

Alphamab Oncology Licenses Cancer Drug Candidate to Pathos AI for Up to $2.09 Billion

MT Newswires Live
·
Aug 05

Alphamab Oncology (ALPHAMAB-B) Reports Stable Share Capital and Option Movements for July 2026

Bulletin Express
·
Aug 05

CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China

MT Newswires Live
·
Aug 04